Published in Trends Mol Med on February 20, 2006
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
Surface-enhanced Raman scattering tags for rapid and homogeneous detection of circulating tumor cells in the presence of human whole blood. J Am Chem Soc (2008) 1.45
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res (2008) 1.37
Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem (2009) 1.20
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab Chip (2014) 1.07
Circulating tumor cells, enumeration and beyond. Cancers (Basel) (2010) 1.03
Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer (2011) 0.96
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget (2015) 0.95
Microfluidic electroporation of tumor and blood cells: observation of nucleus expansion and implications on selective analysis and purging of circulating tumor cells. Integr Biol (Camb) (2010) 0.95
Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clin Exp Metastasis (2008) 0.91
Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol (2012) 0.91
Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer (2013) 0.90
Circulating tumor cell enrichment based on physical properties. J Lab Autom (2013) 0.90
New generation of ensemble-decision aliquot ranking based on simplified microfluidic components for large-capacity trapping of circulating tumor cells. Anal Chem (2013) 0.83
Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. J Transl Med (2010) 0.83
Accurate detection of carcinoma cells by use of a cell microarray chip. PLoS One (2012) 0.82
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer (2011) 0.81
Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer (2009) 0.81
High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients. PLoS One (2013) 0.81
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.78
Micro- and nanotechnology approaches for capturing circulating tumor cells. Cancer Nanotechnol (2010) 0.77
Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis. Sci Rep (2016) 0.77
Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma. J Cancer (2015) 0.76
Circulating Tumor Cells in the Adenocarcinoma of the Esophagus. Int J Mol Sci (2016) 0.76
Rare cell isolation and recovery on open-channel microfluidic chip. PLoS One (2017) 0.75
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov (2017) 0.75
Notes for developing a molecular test for the full characterization of circulating tumor cells. Chin J Cancer Res (2015) 0.75
Detection of circulating tumor cells in gastrointestinal cancer: Has its time come? J Gastrointest Oncol (2012) 0.75
Real-Time qPCR-Based Detection of Circulating Tumor Cells from Blood Samples of Adjuvant Breast Cancer Patients: A Preliminary Study. Breast Care (Basel) (2016) 0.75
Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"? Chin J Cancer Res (2012) 0.75
An integrated microfluidic system for the isolation and detection of ovarian circulating tumor cells using cell selection and enrichment methods. Biomicrofluidics (2017) 0.75
Systematic Correlation Analyses of Circulating Tumor Cells with Clinical Variables and Tumor Markers in Lung Cancer Patients. J Cancer (2017) 0.75
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol (2007) 3.15
A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg (2008) 3.14
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology (2008) 2.63
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum (2013) 2.52
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res (2006) 2.36
A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg (2010) 2.27
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol (2008) 1.93
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol (2006) 1.88
Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst (2012) 1.82
Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol (2004) 1.80
Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol (2005) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer (2003) 1.77
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol (2003) 1.75
Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol (2011) 1.69
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol (2008) 1.65
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood (2002) 1.62
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood (2005) 1.58
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 1.55
Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev (2004) 1.55
Automated quantitative evaluation of lymph node perfusion on contrast-enhanced sonography. AJR Am J Roentgenol (2007) 1.55
Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg (2013) 1.53
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst (2006) 1.51
Telomerase and the search for the end of cancer. Trends Mol Med (2012) 1.46
Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer (2005) 1.46
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst (2004) 1.39
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
Natural T cell immunity against cancer. Clin Cancer Res (2003) 1.36
Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol (2009) 1.36
The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev (2004) 1.34
Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer (2004) 1.29
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc (2011) 1.27
Giant fibroadenoma of the breast in adolescents: report of 2 cases. J Pediatr Surg (2009) 1.24
The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer (2009) 1.22
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg (2011) 1.16
TNF and cancer: the two sides of the coin. Front Biosci (2008) 1.15
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol (2006) 1.12
Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer (2012) 1.12
Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res (2008) 1.11
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology (2009) 1.10
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol (2007) 1.10
Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest (2010) 1.09
CMV-specific central memory T cells reside in bone marrow. Eur J Immunol (2007) 1.08
Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev (2005) 1.08
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer (2008) 1.07
The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol (2006) 1.07
Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery (2010) 1.07
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood (2011) 1.06
-174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res (2003) 1.05
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother (2004) 1.04
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer (2008) 1.04
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res (2011) 1.04
Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer (2008) 1.04
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res (2002) 1.03
Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev (2008) 1.02
Evaluation of lymph node perfusion using continuous mode harmonic ultrasonography with a second-generation contrast agent. J Ultrasound Med (2004) 1.02
Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol (2008) 1.02
Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol (2008) 1.01
Gastric cancer and synchronous hepatic metastases: is it possible to recognize candidates to R0 resection? Ann Surg Oncol (2014) 1.01
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations. J Transl Med (2008) 1.01
Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité. Anticancer Res (2009) 1.00
Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer (2009) 1.00
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol (2013) 1.00
Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol (2013) 0.99
DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis (2009) 0.99
Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med (2009) 0.99
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 0.99
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology (2012) 0.98
Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther (2004) 0.97
Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). Ann Surg (2009) 0.97
Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer (2003) 0.97